The effect of nebivolol versus metoprolol succinate extended release on asymmetric dimethylarginine in hypertension

Journal of the American Society of Hypertension

Volumn 5, Issue 3, 2011, Pages 161-165

  Kandavar, Ramprasad ^a   Higashi, Yusuke ^a   Chen, Wei ^a   Blackstock, Christopher ^a   Vaughn, Charlotte ^a   Sukhanov, Sergiy ^a   Sander, Gary E ^a   Roffidal, Louise E ^b   Delafontaine, Patrice ^a   Giles, Thomas D ^a,b  

^a TULANE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Gulf Regional Research and Educational Services LLC   (United States)

Author keywords

Asymmetric dimethylarginine; beta blockers; hypertension; metoprolol succinate; nebivolol

Indexed keywords

CD133 ANTIGEN; FLUORESCEIN; METOPROLOL SUCCINATE; N(G),N(G) DIMETHYLARGININE; NEBIVOLOL; NITRIC OXIDE; PLACEBO; SOMATOMEDIN C;

ADULT; ANTIHYPERTENSIVE ACTIVITY; ANTIHYPERTENSIVE THERAPY; ARTICLE; AUGMENTATION INDEX; BIOAVAILABILITY; CLINICAL ARTICLE; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DOSE RESPONSE; DRUG DOSE TITRATION; DRUG EFFECT; DRUG SAFETY; DRUG TOLERABILITY; ENDOTHELIAL PROGENITOR CELL; ENDOTHELIUM CELL; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; HYPERTENSION; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; STEM CELL; SYSTOLIC BLOOD PRESSURE; TREATMENT DURATION; UNSPECIFIED SIDE EFFECT;

ADMINISTRATION, ORAL; AGED; ANTIHYPERTENSIVE AGENTS; ARGININE; BENZOPYRANS; BLOOD PRESSURE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG MONITORING; ENDOTHELIAL CELLS; ETHANOLAMINES; FEMALE; HUMANS; HYPERTENSION; INSULIN-LIKE GROWTH FACTOR I; MALE; METOPROLOL; MIDDLE AGED; NITRIC OXIDE SYNTHASE; TREATMENT OUTCOME;

EID: 79955633341     PISSN: 19331711     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jash.2010.11.003     Document Type: Article

References (20)

1. Vallance P, Leone A, Calver A, Colier J, Moncada S. Accumulation of an endogenous inhibitor of nitric oxide synthesis in chronic renal failure. Lancet 1992; 339:572-5.
2. MacAllister RJ, Fickling SA, Whitley GS, Vallance P. Metabolism of methylarginines by human vasculature: implications for the regulation of nitric oxide synthesis. Br J Pharmacol 1994;112:43-8. (Pubitemid 24151701)
3. Toth J, Racz A, Kaminski PM, Wolin MS, Bagi Z, Koller A. Asymmetrical dimethylarginine inhibits shear stress-induced nitric oxide release and dilation and elicits superoxide-mediated increase in arteriolar tone. Hypertension 2007;49:563-8.
4. Böger BH, Sullivan LM, Schwedheim E, Wang TJ, Maas R, Benjamin EJ, et al. Plasma asymmetric dimethylarginine and incidence of cardiovascular disease and death in the community. Circulation 2009;119: 1592-600.
5. Ignarro LJ. Different pharmacological properties of two enantiomers in a unique β-blocker, nebivolol. Cardiovasc Therapeutics 2008;26:115-34. (Pubitemid 351952828)
6. Evangelista S, Garbin U, Prasini AF, Stranieri C, Boccioletti V, Cominacini L. Effect of DL-nebivolol, its enantiomers and metabolites on the intracellular production of superoxide and nitric oxide in human endothelial cells. Pharmacol Res 2007;55:303-9. (Pubitemid 46533933)
7. Bank A, Kelly AS, Thelen AM, Kaiser DR, Gonzalez-Campoy JM. Effects of carvedilol versus metoprolol on endothelial function and oxidative stress in patients with type 2 diabetes mellitus. Am J Hypertens 2007;20:777-83. (Pubitemid 46936169)
8. Garbin U, Pasini AF, Stranieri C, Manfro S, Boccioletti V, Cominacini L. Nebivolol reduces asymmetric dimethylarginine in endothelial cells by increasing dimethylarginine dimethylaminohydrolase 2 (DDAH2) expression and activity. Pharmacol Res 2007;56:515-21. (Pubitemid 350137774)
9. Thum T, Fleissner F, Klink I, Tsikas D, Jakob M, Bauersachs J, Stichtenoth DO. Growth hormone treatment improves markers of systemic nitric oxide bioavailability via insulin-like growth factor-1. J Clin Endocrinol Metab 2007;92:4172-9. (Pubitemid 350074728)
10. Michell BJ, Griffiths JE, Mitchehill KL, Rodriguez-Crespo I, Tiganis T, Bozinovski S, et al. The Akt kinase signals directly to endothelial nitric oxide synthase. Curr Biol 1999;9:845-80.
11. Shantsila E, Watson T, Lip GYH. Endothelial progenitor cells in cardiovascular disorders. J Am Coll Cardiol 2007;49:7412-52.
12. Kielstein JT, Donnerstag F, Gasper S, Menne J, Kielstein A, Martens-Lobenhoffer J, et al. ADMA increases arterial stiffness and decreases cerebral blood flow in humans. Stroke 2006;37:2024-9. (Pubitemid 44309898)
13. Oǧuz A, Uzunlulu M, Yoruimaz E, Yalçin Y, Helim N, Fici F. Effect of nebivolol and metoprolol treatments on serum asymmetric dimethylarginine levels in hypertensive patients with type 2 diabetes mellitus. Anadolu Kardiyol Derg 2007;7:383-7. (Pubitemid 350303384)
14. Pasini AF, Garbin U, Stranier C, Boccioletti V, Mozzini C, Manfro S, et al. Nebivolol treatment reduces serum levels of asymmetric dimethylarginine and improves endothelial dysfunction in essential hypertensive patients. Am J Hypertens 2008;21:1251-7.
15. Rosner B. Fundamentals of biostatistics. 5th ed. Boston, MA: Duxbury Press; 2000:309-12.
16. Valkonen VP, Tuomainen TP, Laaksonen R. DDAH gene and cardiovascular risk. Vasc Med 2005;(Suppl 1): S45-6.
17. Ufer C, Germack R. Cross-regulation between β1- and β3-adrenoceptors following chronic β-adrenergic stimulation in neonatal rat cardiomyocytes. Br J Pharmacol 2009;158:300-13.
18. Rozec B, Erfanian M, Laurent K, Trochu J-N, Gautheir C. Nebivolol, a vasodilating selective β1-blocker, is a β3-adrenoceptor agonist in the nonfailing transplanted human heart. J Am Coll Cardiol 2009; 53:1532-8.
19. Shimizu M, Kario K. Role of the augmentation index in hypertension. Therapeut Adv Cardiovasc Dis 2008;2: 25-35. (Pubitemid 351583140)
20. Delva P, Degan M, Vallerio P, et al. Endothelial progenitor cells in patients with essential hypertension. J Hypertens 2007;25:2093-9.